Krystal Biotech (KRYS)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Krystal Biotech (KRYS)
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.
Key Insights
Critical company metrics and information
Share Price
$184.15Market Cap
$5.30 BillionTotal Outstanding Shares
28.76 Million SharesTotal Employees
229Dividend
No dividendIPO Date
September 20, 2017SIC Description
Biological Products, (no Disgnostic Substances)Homepage
https://www.krystalbio.com
Historical Stock Splits
Execution Date | Split Amount |
---|---|
No Historical Stock Splits |
Cash Flow Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Net Cash Flow From Financing Activities, Continuing | $27.20 Million |
Net Cash Flow From Financing Activities | $27.20 Million |
Exchange Gains/Losses | $-4,000.00 |
Net Cash Flow, Continuing | $729,000.00 |
Net Cash Flow From Operating Activities, Continuing | $63.34 Million |
Net Cash Flow From Investing Activities | $-89.82 Million |
Net Cash Flow | $725,000.00 |
Net Cash Flow From Investing Activities, Continuing | $-89.82 Million |
Net Cash Flow From Operating Activities | $63.34 Million |
Income Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Net Income/Loss Available To Common Stockholders, Basic | $52.37 Million |
Preferred Stock Dividends And Other Adjustments | $0.00 |
Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
Diluted Earnings Per Share | $1.78 |
Diluted Average Shares | $30.04 Million |
Revenues | $241.52 Million |
Income Tax Expense/Benefit | $5.03 Million |
Operating Expenses | $214.06 Million |
Operating Income/Loss | $27.45 Million |
Research and Development | $51.42 Million |
Net Income/Loss | $52.37 Million |
Basic Earnings Per Share | $1.85 |
Net Income/Loss Attributable To Parent | $52.37 Million |
Income/Loss From Continuing Operations Before Tax | $57.40 Million |
Other Operating Expenses | $153.88 Million |
Benefits Costs and Expenses | $184.12 Million |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
Costs And Expenses | $184.12 Million |
Income/Loss From Continuing Operations After Tax | $52.37 Million |
Basic Average Shares | $28.88 Million |
Balance Sheet
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Noncurrent Assets | $269.15 Million |
Current Assets | $713.16 Million |
Inventory | $18.58 Million |
Liabilities And Equity | $982.32 Million |
Other Current Liabilities | $83.95 Million |
Fixed Assets | $156.59 Million |
Cash | $588.30 Million |
Assets | $982.32 Million |
Noncurrent Liabilities | $6.95 Million |
Current Liabilities | $89.53 Million |
Liabilities | $96.47 Million |
Other Current Assets | $106.28 Million |
Accounts Payable | $5.58 Million |
Equity Attributable To Parent | $885.85 Million |
Equity | $885.85 Million |
Equity Attributable To Noncontrolling Interest | $0.00 |
Other Non-current Assets | $112.56 Million |
Historical Dividends
Announcement Date | Payment Date | Record Date | Amount | Frequency |
---|---|---|---|---|
No historical dividends |
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
â“’ 2024 Financhle. All Rights Reserved.